Advertisement

Topics

Search Results for "Mirrx Therapeutics"

04:19 EDT 26th June 2016 | BioPortfolio

Matching Channels

Tuberculosis Vaccines and Therapeutics

The WHO estimates that the largest number of new tuberculosis (TB) cases in 2008 occurred in the South-East Asia Region, which accounted for 34% of incident cases globally. However, the estimated inci...

KIACTA

KIACTA™ (also known as eprodisate) is an orally bioavailable small molecule intended for the treatment of AA amyloidosis, an orphan indication that results from long-standing inflammatory cond...

Anthrax Vaccines and Therapeutics

Anthrax is a zoonotic disease caused by the spore-forming bacterium Bacillus anthracis. The disease most commonly occurs in mammals (e.g., cattle, sheep, goats, camels, antelope. Anthrax occurs in hu...

AUT00063

AUT00063 develpoed by Autifony Therapeutics, is a novel, orally active small molecule designed to selectively modulate Kv3 potassium channels, which are important in central auditory processing. Pre...

Facebook - BioPortfolio Pages

BioPortfolio has launched a number of Facebook pages to allow our visitors to keep track with latest news, published paper and clinical trials by lead biotechnology and healthcare topics:- &nbs...

Matching News

BIND Therapeutics collaborates with Affilogic

BIND Therapeutics, a company developing targeted and programmable therapeutics called ACCURINS, has signed…

Placon Therapeutics launches, BTP-114 IND accepted by FDA

Placon Therapeutics, a biotechnology company developing next-generation platinum-based cancer therapies, has launched as an independent company and provided an update on its lead product candidate, BT...

Bicycle Therapeutics establishes U.S. operations

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptides (Bicycles) platform, has established U.S. operations with headquarters i...

Living Therapeutics

An MIT spinout, Synlogic, is aiming to create a new class of medicines, by re-programming bacteria found in the gut as “living therapeutics.”Read more about Living Therapeutics Comments

Tarveda spins platinum-based drug assets out into newco Placon Therapeutics

Tarveda Therapeutics Inc. (formerly Blend Therapeutics) spun out its development-stage platinum-based cancer assets into a new independent entity named Placon Therapeutics.

Wilson Therapeutics AB: Change in Number of Shares in Wilson Therapeutics

Regulatory News: Wilson Therapeutics (STO:WTX) The number of shares and votes in Wilson Therapeutics AB (publ) has changed as a result of the new issue of shares that was made in connection with t...

Intensity Therapeutics Inc.

Intensity Therapeutics Inc.'s DfuseRx platform combines known, potent chemotherapeutics with cell-penetration enhancing compounds. The resulting therapeutics are designed to kill tumor cells in masse...

AstraZeneca to collaborate with Moderna Therapeutics to develop mRNA therapeutics

Anglo-Swedish pharma company AstraZeneca will join forces with US biotech firm Moderna Therapeutics to…

Matching PubMed Articles

Injectable biomaterials: a perspective on the next wave of injectable therapeutics.

We are experiencing a new wave of injectable therapeutics (namely/injectable biomaterials) to complement injectable drugs and injectable biologics, and to serve as the basis for injectable combinatori...

Pigmentation and Macular Degeneration: Is There a Role for GPR143?

Fit for the Eye: Aptamers in Ocular Disorders.

For any new class of therapeutics, there are certain types of indications that represent a natural fit. For nucleic acid ligands in general, and aptamers in particular, the eye has historically been a...

Eyes on New Product Development.

Reviewer Acknowledgment 2015.

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement